While SGLT2 inhibitor-based regimens may offer enhanced benefit in patients with high diabetes burden, applying intensive combination therapies to frail individuals with multimorbidity, poor nutrition, or polypharmacy requires meticulous individualization. This evidence concerns the gene SLC5A2 and diabetes mellitus.